{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:44:58Z","timestamp":1790390698670,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["116030"],"award-info":[{"award-number":["116030"]}]},{"name":"European Union's Horizon 2020"},{"DOI":"10.13039\/100013322","name":"EFPIA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vascn.2019.106654","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T19:49:58Z","timestamp":1573588198000},"page":"106654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure"],"prefix":"10.1016","volume":"101","author":[{"given":"Derek J.","family":"Leishman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vascn.2019.106654_bb0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.0306-5251.2001.01511.x","article-title":"Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval","volume":"53","author":"Allen","year":"2002","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"13","key":"10.1016\/j.vascn.2019.106654_bb0010","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Reports"},{"issue":"2","key":"10.1016\/j.vascn.2019.106654_bb0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","article-title":"Comparative pharmacology of risperidone and paliperidone","volume":"15","author":"Corena-McLeod","year":"2015","journal-title":"Drugs in R&D"},{"issue":"6","key":"10.1016\/j.vascn.2019.106654_bb0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/eurheartj\/ehi092","article-title":"Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death","volume":"26","author":"De Bruin","year":"2005","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1016\/j.vascn.2019.106654_bb0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"2","key":"10.1016\/j.vascn.2019.106654_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pharmthera.2010.08.008","article-title":"An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation","volume":"129","author":"Gintant","year":"2011","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.vascn.2019.106654_bb0035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.vascn.2019.106654_bb0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ddr.430080109","article-title":"Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man","volume":"8","author":"Heykants","year":"1986","journal-title":"Drug Development Research"},{"key":"10.1016\/j.vascn.2019.106654_bb0045","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","article-title":"Terfenadine-ketoconazole interaction - pharmacokinetic and electrocardiographic consequences","volume":"269","author":"Honig","year":"1993","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vascn.2019.106654_bb0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/clpt.1992.135","article-title":"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin","volume":"52","author":"Honig","year":"1992","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"10.1016\/j.vascn.2019.106654_bb0055","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clpt.2005.02.004","article-title":"A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data","volume":"77","author":"Jonker","year":"2005","journal-title":"Clinical Pharmacology & Amp; Therapeutics"},{"key":"10.1016\/j.vascn.2019.106654_bb0060","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/srep02100","article-title":"MICE models: Superior to the HERG model in predicting torsade de pointes","volume":"3","author":"Kramer","year":"2013","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1016\/j.vascn.2019.106654_bb0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0009-9236(95)90038-1","article-title":"Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization","volume":"57","author":"Le Coz","year":"1995","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"8","key":"10.1016\/j.vascn.2019.106654_bb0070","first-page":"1","article-title":"Predicting QTc prolongation in man from only in vitro data","volume":"3","author":"Leishman","year":"2014","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2019.106654_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004628","article-title":"Improving the in silico assessment of proarrhythmia risk by combining hERG (human ether-a-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology","volume":"10","author":"Li","year":"2017","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"key":"10.1016\/j.vascn.2019.106654_bb0080","first-page":"1502","article-title":"Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative","volume":"154","author":"Li","year":"2018","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"6","key":"10.1016\/j.vascn.2019.106654_bb0085","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metabolism and Disposition"},{"issue":"4","key":"10.1016\/j.vascn.2019.106654_bb0090","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/BF02244986","article-title":"Plasma protein binding of risperidone and its distribution in blood","volume":"114","author":"Mannens","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.vascn.2019.106654_bb0095","first-page":"e130","article-title":"Interaction between domperidone and ketoconazole: Toward prediction of consequent QTc prolongation using purely in vitro information","volume":"3","author":"Mishra","year":"2014","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2019.106654_bb0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1113\/jphysiol.1962.sp006849","article-title":"A modification of the Hodgkin\u2014Huxley equations applicable to Purkinje fibre action and pacemaker potentials","volume":"160","author":"Noble","year":"1962","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.vascn.2019.106654_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2017.00668","article-title":"Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity","volume":"8","author":"Passini","year":"2017","journal-title":"Frontiers in Physiology"},{"issue":"3","key":"10.1016\/j.vascn.2019.106654_bb0110","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-8703(96)90525-6","article-title":"Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability","volume":"131","author":"Pratt","year":"1996","journal-title":"American Heart Journal"},{"issue":"24","key":"10.1016\/j.vascn.2019.106654_bb0115","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1161\/01.CIR.0000019513.50928.74","article-title":"Pharmacological rescue of human K(+) channel long-QT2 mutations: Human ether-a-go-go-related gene rescue without block","volume":"105","author":"Rajamani","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vascn.2019.106654_bb0120","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0026-895X(25)13362-2","article-title":"Effects of terfenadine and its metabolites on a delayed rectifier k channel cloned from human heart","volume":"44","author":"Rampe","year":"1993","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.vascn.2019.106654_bb0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0025-6196(12)62252-6","article-title":"Torsades de pointes ventricular tachycardia associated with overdose of astemizole","volume":"69","author":"Rao","year":"1994","journal-title":"Mayo Clinic Proceedings"},{"issue":"1","key":"10.1016\/j.vascn.2019.106654_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"issue":"5","key":"10.1016\/j.vascn.2019.106654_bb0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003088-199937050-00003","article-title":"Clinical pharmacokinetics of clarithromycin","volume":"37","author":"Rodvold","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"issue":"3","key":"10.1016\/j.vascn.2019.106654_bb0140","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the cardiac safety research consortium","volume":"167","author":"Sager","year":"2014","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1016\/j.vascn.2019.106654_bb0145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.euroneuro.2017.11.009","article-title":"Pharmacokinetics of risperidone in different application forms - comparing long-acting injectable and oral formulations","volume":"28","author":"Schoretsanitis","year":"2018","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2019.106654_bb0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hup.1258","article-title":"QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone","volume":"27","author":"Suzuki","year":"2012","journal-title":"Human Psychopharmacology"},{"issue":"5","key":"10.1016\/j.vascn.2019.106654_bb0155","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10928-018-9597-6","article-title":"Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals","volume":"45","author":"Tylutki","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"6","key":"10.1016\/j.vascn.2019.106654_bb0160","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/FJC.0b013e318217d941","article-title":"Prolongation of cardiac ventricular repolarization under paliperidone: How and how much?","volume":"57","author":"Vigneault","year":"2011","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"6","key":"10.1016\/j.vascn.2019.106654_bb0165","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/S0735-1097(96)00352-X","article-title":"Torsade de pointes with an antihistamine metabolite: Potassium channel blockade with desmethylastemizole","volume":"28","author":"Vorperian","year":"1996","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.vascn.2019.106654_bb0170","first-page":"116","article-title":"Towards a drug concentration effect relationship for QT prolongation and torsades de pointes","volume":"5","author":"Webster","year":"2002","journal-title":"Current Opinion in Drug Discovery & Development"},{"key":"10.1016\/j.vascn.2019.106654_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vascn.2015.05.002","article-title":"A web portal for in-silico action potential predictions","volume":"75","author":"Williams","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"6","key":"10.1016\/j.vascn.2019.106654_bb0180","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1540-8167.1999.tb00264.x","article-title":"Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole","volume":"10","author":"Zhou","year":"1999","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"3","key":"10.1016\/j.vascn.2019.106654_bb0185","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1745-7254.2006.00256.x","article-title":"Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia","volume":"27","author":"Zhou","year":"2006","journal-title":"Acta Pharmacologica Sinica"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871919304125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871919304125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:04:17Z","timestamp":1761005057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871919304125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":37,"alternative-id":["S1056871919304125"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2019.106654","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2019.106654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106654"}}